Type 2 diabetes and SUBTOPIC

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

Read our quick round-up of the LEAD trials of the daily injectable GLP-1 receptor agonist liraglutide in people with type 2 diabetes.

Read our quick round-up of the GetGoal trials of the daily injectable GLP-1 receptor agonist lixisenatide in people with type 2 diabetes.

Sanjay Kalra explains why it is so important for healthcare professionals anywhere in the world to understand about Ramadan and the ramifications for people with diabetes.

We round up the medications currently approved for treating type 2 diabetes in children and adolescents and look at what agents are coming through clinical trials.

Why and how does ethnicity influence risk and management approach for pediatric type 2 diabetes? We talk to childhood obesity specialist Julian Hamilton-Shield.

Torsten Olbers puts the case for metabolic surgery as a treatment option for children with type 2 diabetes.

Read this Hot Topic Review to catch up on the latest research into the risks and benefits of fasting for people with diabetes.

Read our quick round-up of the DURATION trials of the weekly formulation of the GLP-1 receptor agonist exenatide in people with type 2 diabetes.

Read our quick round-up of the AWARD trials of the GLP-1 receptor agonist dulaglutide in people with type 2 diabetes.

John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

Sanjay Kalra explains how use of alpha-glucosidase inhibitors in people with type 2 diabetes can complicate the treatment of hypoglycemia.

In the second article of this series, Sanjay Kalra describes the issue of reactive hypoglycemia and how to best manage it.

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

What makes some people more likely than others to have suicidal thoughts? We outline the risk factors and circumstances that can play a role.

How frequent are suicide deaths in people with diabetes, and can the data be trusted?

Screening, emergency protocols, and person-centered care – just some of the ways healthcare professionals can identify and support people at increased risk for suicide. Click through for more.

Mary de Groot explains the importance of screening for suicidal ideation in people with diabetes, and addresses common concerns that may make doctors hesitate to do so (7:22).

Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.